| Universite Paris Sud XI Patent applications |
| Patent application number | Title | Published |
|---|
| 20120088715 | MUTATED ANTITHROMBINS, A PROCESS FOR PREPARING THE SAME AND THEIR USE AS DRUGS - The present invention relates to the use of a composition including of at least a mutated antithrombin
| 04-12-2012 |
| 20120088186 | Catalyst and Method for the Electrochemical Oxidation of Methane - The invention relates to a catalyst, to the use thereof for the electrochemical conversion of methane to methanol and for the direct electrochemical conversion of methane to CO | 04-12-2012 |
| 20110229411 | USE OF P2X7 PATHWAY FOR ASSESSING THE SENSITIVITY OF A SUBJECT TO A CANCER TREATMENT - The present invention concerns methods for assessing the sensibility of a subject to an anticancer treatment, for screening compounds which are useful for treating a cancer and for determining the likelihood of a metastatic relapse in a subject. The methods are based on the finding that a non-functional P2X7-elicited NALP3 inflammasome pathway in a subject is indicative of a resistance to treatment. The invention further concerns methods for treating a cancer and for restoring the sensitivity of the subject to a cancer treatment. | 09-22-2011 |
| 20110136685 | METHOD FOR DETERMINING A PREDISPOSITION TO BASAL CELL CARCINOMA AND FOR SCREENING TREATMENTS THEREOF - The present invention relates to methods for detecting a predisposition to a basal cell carcinoma and methods for screening a treatment of a basal cell carcinoma. | 06-09-2011 |
| 20100305030 | NANOPARTICLES OF THERAPEUTIC AGENTS HAVING LOW WATER SOLUBILITY - The invention relates to a water-dispersible derivative of a therapeutic agent having a low water solubility that comprises at least one molecule of said agent covalently bonded to at least one molecule of a hydrocarbon derivative having a squalenic structure or the like. The invention further relates to corresponding nanoparticles. | 12-02-2010 |
| 20100298224 | USE OF MUTATED ANTITHROMBINS FOR TREATING OR PREVENTING COAGULATION DISORDERS - Use of a mutated antithrombin having substantially no activity, in particular no anticoagulant activity, possibly in association with an anticoagulant, for the preparation of a drug intended for the prevention or treatment of pathologies linked to or associated with coagulation disorders. | 11-25-2010 |
| 20100267112 | USE OF PKS 13 PROTEIN CODING FOR CONDENSASE OF MYCOLIC ACIDS OF MYCOBACTERIA AND RELATED STRAINS AS AN ANTIBIOTICS TARGET - The invention relates to a novel enzyme involved in the biosynthesis of mycolic acids and to the use thereof for the screening of antibiotics, especially antimycobacterials. The invention more particularly relates to the Pks13 protein which catalyzes Claisen condensation or malonic condensation in mycolates between an acyl-CoA molecule or an acyl-AMP molecule and an acylmalonyl-CoA molecule to form an intermediate β-cEto acyl or β-cEto ester. | 10-21-2010 |
| 20090016098 | MAGNETORESISTIVE DEVICE - A method of operating a magnetoresistive device is described. The device comprises a ferromagnetic region configured to exhibit magnetic anisotropy and to allow magnetisation thereof to be switched between at least first and second orientations and a gate capacitively coupled to the ferromagnetic region. The method comprises applying an electric field pulse to the ferromagnetic region so as to cause orientation of magnetic anisotropy to change for switching magnetisation between the first and second orientations. | 01-15-2009 |
